197 related articles for article (PubMed ID: 26092348)
1. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
De Vos A; Jacobs D; Struyfs H; Fransen E; Andersson K; Portelius E; Andreasson U; De Surgeloose D; Hernalsteen D; Sleegers K; Robberecht C; Van Broeckhoven C; Zetterberg H; Blennow K; Engelborghs S; Vanmechelen E
Alzheimers Dement; 2015 Dec; 11(12):1461-1469. PubMed ID: 26092348
[TBL] [Abstract][Full Text] [Related]
2. CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia.
Clarke MTM; Brinkmalm A; Foiani MS; Woollacott IOC; Heller C; Heslegrave A; Keshavan A; Fox NC; Schott JM; Warren JD; Blennow K; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2019 Dec; 11(1):105. PubMed ID: 31847891
[TBL] [Abstract][Full Text] [Related]
3. Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease.
Xue M; Sun FR; Ou YN; Shen XN; Li HQ; Huang YY; Dong Q; Tan L; Yu JT;
Aging (Albany NY); 2020 May; 12(10):9365-9379. PubMed ID: 32421689
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum.
Goossens J; Cervantes González A; Dewit N; Lidón L; Fortea J; Alcolea D; Lleó A; Belbin O; Vanmechelen E
Alzheimers Res Ther; 2023 Oct; 15(1):186. PubMed ID: 37898760
[TBL] [Abstract][Full Text] [Related]
5. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease.
Vogt NM; Romano KA; Darst BF; Engelman CD; Johnson SC; Carlsson CM; Asthana S; Blennow K; Zetterberg H; Bendlin BB; Rey FE
Alzheimers Res Ther; 2018 Dec; 10(1):124. PubMed ID: 30579367
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
Dage JL; Eloyan A; Thangarajah M; Hammers DB; Fagan AM; Gray JD; Schindler SE; Snoddy C; Nudelman KNH; Faber KM; Foroud T; Aisen P; Griffin P; Grinberg LT; Iaccarino L; Kirby K; Kramer J; Koeppe R; Kukull WA; La Joie R; Mundada NS; Murray ME; Rumbaugh M; Soleimani-Meigooni DN; Toga AW; Touroutoglou A; Vemuri P; Atri A; Beckett LA; Day GS; Graff-Radford NR; Duara R; Honig LS; Jones DT; Masdeu JC; Mendez MF; Musiek E; Onyike CU; Riddle M; Rogalski E; Salloway S; Sha SJ; Turner RS; Wingo TS; Wolk DA; Womack KB; Carrillo MC; Dickerson BC; Rabinovici GD; Apostolova LG;
Alzheimers Dement; 2023 Nov; 19 Suppl 9(Suppl 9):S115-S125. PubMed ID: 37491668
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of plasma pTau
Arranz J; Zhu N; Rubio-Guerra S; Rodríguez-Baz Í; Ferrer R; Carmona-Iragui M; Barroeta I; Illán-Gala I; Santos-Santos M; Fortea J; Lleó A; Tondo M; Alcolea D
Alzheimers Res Ther; 2024 Jun; 16(1):139. PubMed ID: 38926773
[TBL] [Abstract][Full Text] [Related]
9. Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
Li Y; Yen D; Hendrix RD; Gordon BA; Dlamini S; Barthélemy NR; Aschenbrenner AJ; Henson RL; Herries EM; Volluz K; Kirmess K; Eastwood S; Meyer M; Heller M; Jarrett L; McDade E; Holtzman DM; Benzinger TLS; Morris JC; Bateman RJ; Xiong C; Schindler SE
Ann Neurol; 2024 May; 95(5):951-965. PubMed ID: 38400792
[TBL] [Abstract][Full Text] [Related]
10. Neurogranin in Alzheimer's disease and ageing: A human post-mortem study.
Saunders T; Gunn C; Blennow K; Kvartsberg H; Zetterberg H; Shenkin SD; Cox SR; Deary IJ; Smith C; King D; Spires-Jones T
Neurobiol Dis; 2023 Feb; 177():105991. PubMed ID: 36623608
[TBL] [Abstract][Full Text] [Related]
11. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.
Mielke MM; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Vemuri P; Machulda MM; Graff-Radford J; Knopman DS; Jack CR; Petersen RC; Kern S
Alzheimers Dement; 2019 Nov; 15(11):1437-1447. PubMed ID: 31668594
[TBL] [Abstract][Full Text] [Related]
12. C1q is increased in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: A multi-cohort proteomics and immuno-assay validation study.
Chatterjee M; Özdemir S; Kunadt M; Koel-Simmelink M; Boiten W; Piepkorn L; Pham TV; Chiasserini D; Piersma SR; Knol JC; Möbius W; Mollenhauer B; van der Flier WM; Jimenez CR; Teunissen CE; Jahn O; Schneider A
Alzheimers Dement; 2023 Nov; 19(11):4828-4840. PubMed ID: 37023079
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression.
Siafarikas N; Kirsebom BE; Srivastava DP; Eriksson CM; Auning E; Hessen E; Selbaek G; Blennow K; Aarsland D; Fladby T
Sci Rep; 2021 Oct; 11(1):20375. PubMed ID: 34645914
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.
Camporesi E; Nilsson J; Vrillon A; Cognat E; Hourregue C; Zetterberg H; Blennow K; Becker B; Brinkmalm A; Paquet C; Brinkmalm G
EBioMedicine; 2022 Jan; 75():103793. PubMed ID: 34990894
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach.
Timsina J; Gomez-Fonseca D; Wang L; Do A; Western D; Alvarez I; Aguilar M; Pastor P; Henson RL; Herries E; Xiong C; Schindler SE; Fagan AM; Bateman RJ; Farlow M; Morris JC; Perrin RJ; Moulder K; Hassenstab J; Vöglein J; Chhatwal J; Mori H; ; ; Sung YJ; Cruchaga C
J Alzheimers Dis; 2022; 89(1):193-207. PubMed ID: 35871346
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders.
Nilsson J; Cousins KAQ; Gobom J; Portelius E; Chen-Plotkin A; Shaw LM; Grossman M; Irwin DJ; Trojanowski JQ; Zetterberg H; Blennow K; Brinkmalm A
Alzheimers Dement; 2023 May; 19(5):1775-1784. PubMed ID: 36239248
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.
Dhiman K; Blennow K; Zetterberg H; Martins RN; Gupta VB
Cell Mol Life Sci; 2019 May; 76(10):1833-1863. PubMed ID: 30770953
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil.
Alvarez XA; Winston CN; Barlow JW; Sarsoza FM; Alvarez I; Aleixandre M; Linares C; García-Fantini M; Kastberger B; Winter S; Rissman RA
J Alzheimers Dis; 2022; 90(2):705-717. PubMed ID: 36155516
[TBL] [Abstract][Full Text] [Related]
19. Retinol Binding Protein 4 Levels Are Not Altered in Preclinical Alzheimer's Disease and Not Associated with Cognitive Decline or Incident Dementia.
Ishii M; Kamel H; Iadecola C
J Alzheimers Dis; 2019; 67(1):257-263. PubMed ID: 30562901
[TBL] [Abstract][Full Text] [Related]
20. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease.
Galasko D; Xiao M; Xu D; Smirnov D; Salmon DP; Dewit N; Vanbrabant J; Jacobs D; Vanderstichele H; Vanmechelen E; ; Worley P
Alzheimers Dement (N Y); 2019; 5():871-882. PubMed ID: 31853477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
